Benitec Biopharma (BNTC) AI Stock Analysis

• Market Cap: $325.24M
• Dividend Yield: N/A
• Average Volume (3M): 72.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: -100.00%
• EPS Growth: 83.98%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 26,250,470
• 10 Day Avg. Volume: 45,953
• 30 Day Avg. Volume: 72,694
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.23
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -4.39K
• Enterprise Value/Ebitda: -13.34
• 1Y Price Target: $22.63
• Price Target Upside: 78.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 47 Neutral
• Price Target: $12.50 ▼(-1.26% Downside)

Benitec Biopharma's stock score is primarily driven by weak financial performance, reflected in large net losses and negative cash flow. The technical outlook is bearish, and valuation concerns arise from a negative P/E ratio. However, the recent positive corporate event provides a glimmer of potential growth, slightly boosting the score.

Positive Factors

Clinical Trials

BB-301's Phase 1/2 clinical data showed significant improvements in dysphagia measures for OPMD patients, indicating promising therapeutic potential.

Financial Performance

Benitec Biopharma reported a net loss of only $0.24 per share, beating the forecasted net loss of $0.36 per share, reflecting better-than-expected financial performance.

Funding and Cash Reserves

Benitec Biopharma ended the period with $103.6 million in cash and equivalents, providing sufficient funding to support operations for the next 18 to 24 months.

Negative Factors

Clinical Trial Risks

Risks include slower-than-expected progress in the ongoing clinical trial of BB-301 and the potential for emergence of unexpected side effects.

Stock Offering

The secondary offering is priced at $13 per share, which may lead to shareholder dilution.

Benitec Biopharma Business Overview & Revenue Model

Company Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

How the Company Makes Money

Benitec Biopharma generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These agreements often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of therapies utilizing their ddRNAi technology. Additionally, Benitec may receive funding from grants and research institutions to support their research and development efforts.

Benitec Biopharma Financial Statement Overview

Summary

Benitec Biopharma's financial performance is weak, with significant net losses, negative cash flow, and inconsistent revenue growth. Despite a strong equity position and recent financing, the company's financial instability poses substantial risks.

Income Statement

The income statement shows a declining revenue trend with a significant net loss and negative margins. The TTM (Trailing-Twelve-Months) data indicates a gross profit margin of -2916.67%, a net profit margin of -356916.67%, and an EBIT margin of -401550%. Revenue growth is inconsistent, showing a decline compared to previous periods, reflecting challenges in generating sales.

Balance Sheet

Benitec Biopharma's balance sheet shows a strong equity position with an equity ratio of 96.11% in TTM. However, the debt-to-equity ratio is low at 0.002, indicating minimal leverage. The return on equity is negative, reflecting ongoing net losses. The company maintains a robust cash position, providing some stability.

Cash Flow

The cash flow statement highlights negative operating cash flow and free cash flow in TTM. The free cash flow growth rate is negative, indicating cash burn. However, the company raised substantial financing, improving liquidity. The operating cash flow to net income ratio is close to 1, suggesting cash flow issues align with net losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	216.00K	75.00K	73.00K	59.00K	97.00K
Gross Profit	108.00K	-306.00K	64.00K	-64.00K	-171.06K
EBITDA	-22.49M	-18.70M	-17.85M	-13.60M	-7.91M
Net Income	-21.75M	-19.56M	-18.56M	-13.78M	-8.30M
Balance Sheet
Total Assets	52.21M	4.46M	5.97M	21.38M	11.59M
Cash, Cash Equivalents and Short-Term Investments	50.87M	2.48M	4.06M	19.77M	9.80M
Total Debt	284.00K	559.00K	811.00K	213.00K	405.00K
Total Liabilities	4.96M	4.26M	3.09M	1.37M	1.35M
Stockholders Equity	47.25M	202.00K	2.88M	20.01M	10.24M
Cash Flow
Free Cash Flow	-19.58M	-18.01M	-15.91M	-13.05M	-7.63M
Operating Cash Flow	-19.40M	-18.01M	-15.90M	-12.83M	-7.54M
Investing Cash Flow	-179.00K	-1.00K	-13.00K	-221.00K	-94.00K
Financing Cash Flow	68.03M	16.02M	0.00	22.52M	1.77M

Benitec Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.66
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Positive. The current price of 12.66 is above the 20-day moving average (MA) of 11.57, below the 50-day MA of 13.04, and above the 200-day MA of 12.42, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 57.11 is Neutral, neither overbought nor oversold. The STOCH value of 90.81 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNTC.

Benitec Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ETON	66 Neutral	$464.48M	―	-22.06%	―	85.40%	40.95%
ZBIO	58 Neutral	$665.16M	―	-88.40%	―	―	―
PHAT	56 Neutral	$736.40M	―	181.41%	―	1049.81%	7.85%
AMLX	56 Neutral	$731.17M	―	-87.42%	―	-100.08%	-2.45%
Sector *	51 Neutral	$7.44B	-0.20	-46.00%	2.27%	22.80%	-2.27%
BNTC	47 Neutral	$325.24M	―	-48.57%	―	-100.00%	83.98%
CKPT	45 Neutral	$370.71M	―	-1869.55%	―	-60.19%	56.60%

Benitec Biopharma Corporate Events

Benitec Biopharma Advances BB-301 Clinical Study

On July 9, 2025, Benitec Biopharma announced that the sixth and final subject of Cohort 1 was safely treated with a low dose of BB-301 in their Phase 1b/2a Clinical Treatment Study. Following a positive recommendation from the Data Safety Monitoring Board, the company plans to begin enrolling subjects for Cohort 2 in the fourth quarter of 2025. This development marks a significant step in advancing their gene therapy program, potentially enhancing Benitec’s position in the biotechnology industry and offering hope for stakeholders involved in the treatment of OPMD.

The most recent analyst rating on (BNTC) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Benitec Biopharma stock, see the BNTC Stock Forecast page.